MX9803253A - Metodo para el tratamiento de colitis establecida utilizando anticuerpos contra il-12. - Google Patents

Metodo para el tratamiento de colitis establecida utilizando anticuerpos contra il-12.

Info

Publication number
MX9803253A
MX9803253A MX9803253A MX9803253A MX9803253A MX 9803253 A MX9803253 A MX 9803253A MX 9803253 A MX9803253 A MX 9803253A MX 9803253 A MX9803253 A MX 9803253A MX 9803253 A MX9803253 A MX 9803253A
Authority
MX
Mexico
Prior art keywords
colitis
methods
established colitis
antibodies against
treating established
Prior art date
Application number
MX9803253A
Other languages
English (en)
Inventor
Warren Strober
Ivan Fuss
Markus Neurath
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of MX9803253A publication Critical patent/MX9803253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion proporciona un método para el tratamiento de la respuesta inflamatoria de una colitis establecida en un sujeto con enfermedad inflamatoria del intestino (IBD), el cual comprende administrar a un sujeto diagnosticado con una colitis establecida por una enfermedad inflamatoria del intestino, una cantidad de un anticuerpo para interleucina-12, efectiva para reducir el efecto inductor de colitis de la interleucina-12. También se proporciona un método para rastrear una sustancia por su efectividad para reducir la respuesta inflamatoria de una colitis establecida. Adicionalmente la presente invencion proporciona un método para rastrear una sustancia por su efectividad para prevenir la enfermedad inflamatoria del intestino.
MX9803253A 1995-10-25 1998-04-24 Metodo para el tratamiento de colitis establecida utilizando anticuerpos contra il-12. MX9803253A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/547,979 US5853697A (en) 1995-10-25 1995-10-25 Methods of treating established colitis using antibodies against IL-12

Publications (1)

Publication Number Publication Date
MX9803253A true MX9803253A (es) 1998-09-30

Family

ID=24186934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803253A MX9803253A (es) 1995-10-25 1998-04-24 Metodo para el tratamiento de colitis establecida utilizando anticuerpos contra il-12.

Country Status (10)

Country Link
US (1) US5853697A (es)
EP (1) EP0862461B1 (es)
JP (2) JP4148533B2 (es)
AT (1) ATE296112T1 (es)
AU (1) AU710282B2 (es)
CA (1) CA2235866C (es)
DE (1) DE69634782T2 (es)
ES (1) ES2239329T3 (es)
MX (1) MX9803253A (es)
WO (1) WO1997015327A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683046B1 (en) * 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
EP1085906B1 (en) * 1998-06-10 2008-08-13 Ophidian Pharmaceuticals, Inc. Anti il6 antibodies in the prevention and treatment of inflammatory bowel disease
KR20130105766A (ko) 1999-03-25 2013-09-25 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7186507B2 (en) * 1999-12-09 2007-03-06 Indiana University Research And Technology Corporation Fluorescent in situ RT-PCR
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20050113434A1 (en) * 2003-10-03 2005-05-26 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
SG158150A1 (en) 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
AU2006253006B8 (en) * 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
AU2006253007B2 (en) * 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
WO2007041219A2 (en) * 2005-09-30 2007-04-12 Centocor, Inc. Compositions and methods for il13 biomarkers
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011032148A1 (en) * 2009-09-14 2011-03-17 Abbott Laboratories Methods for treating psoriasis
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
BR112019011702A2 (pt) 2016-12-14 2019-10-22 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
DK3883606T5 (da) 2018-09-24 2024-01-02 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE140483T1 (de) * 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
DK0790308T3 (da) * 1989-12-22 2007-10-08 Hoffmann La Roche Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
CA2121096A1 (en) * 1993-04-22 1994-10-23 Weng Tao Monoclonal antibodies to bovine cytokines
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JPH0769895A (ja) * 1993-08-27 1995-03-14 Tokyo Tanabe Co Ltd 炎症性腸疾患治療剤
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases

Also Published As

Publication number Publication date
DE69634782T2 (de) 2006-03-23
EP0862461B1 (en) 2005-05-25
CA2235866C (en) 2010-09-28
JP4148533B2 (ja) 2008-09-10
ATE296112T1 (de) 2005-06-15
JP2000502991A (ja) 2000-03-14
AU5378696A (en) 1997-05-15
WO1997015327A1 (en) 1997-05-01
ES2239329T3 (es) 2005-09-16
EP0862461A1 (en) 1998-09-09
AU710282B2 (en) 1999-09-16
JP2008169199A (ja) 2008-07-24
CA2235866A1 (en) 1997-05-01
DE69634782D1 (de) 2005-06-30
US5853697A (en) 1998-12-29

Similar Documents

Publication Publication Date Title
MX9803253A (es) Metodo para el tratamiento de colitis establecida utilizando anticuerpos contra il-12.
GB8916400D0 (en) Modified igg3
AU8494291A (en) Methods of treating, diagnosing and monitoring therapies from levels of human oubain-like factor and antibody thereof
ZA931148B (en) Cloning and expression of humanized monoclonal antibodies against human interfluekin-4.
AU3674684A (en) Non-catalytic method for reducing the concentration of no in combustion effluents by injecting ammonia at temperatures greater than about 1300 degree k.
EP0037110A3 (en) Method for enzyme immunoassay and peptide-enzyme conjugate, its lyophilizate, antibody and kit therefor
CA2204616A1 (en) Ppar gamma antagonists for treating obesity
EP0117114A3 (en) Method and device for bacterial testing
ES2121788T3 (es) Anticuerpos dirigidos contra cd3.
HK1015413A1 (en) Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharaceutical compositions
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
FR2617424B1 (fr) Procede pour traiter la rotondite de la semelle d'un culbuteur de moteur, et son dispositif d'execution
MX9604183A (es) Metodo de examen para identificar ligandos para proteinas objetivo.
FI932912A (fi) Testmetod och reagensfoerpackning avsedd foer den
FR2708348B1 (fr) Procédé de dosage d'une substance immunologique au moyen de particules de latex magnétiques et de particules non-magnétiques.
FI971883A (fi) Vasta-aineluokkapesifinen häiriöitä estävä reagenssi
ZA967833B (en) Method and composition for treating mammalian diseases caused by inflammatory response
NL186258C (nl) Werkwijze voor de bereiding van cokes, in het bijzonder naaldcokes.
GR3034891T3 (en) Method and kit for predicting the therapeutic response of a drug against a malignant tumour
CA2362583A1 (en) Assay for the identification of ige antibody suppressors
AU8864791A (en) Antibodies and methods for diagnosis and treatment of diabetes
GR3015489T3 (en) Monoclonal antibodies and process for the diagnosis of phytophtora infections.
FR2659315B1 (fr) Composition et procede de traitement du lisier.
SE9102014D0 (sv) Foerfarande i samband med mammalieceller
FR2745974B1 (fr) Animal modifie, utilisations et procede pour mesurer l'efficacite d'un procede therapeutique

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees